Dr. Stenzl on the Safety Profile of Enzalutamide/ADT in mHSPC

Arnulf Stenzl, MD, medical director of the Department of Urology at the University of Tübingen in Germany, discusses the safety profile of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC).

At the 2020 ASCO Virtual Scientific Program, a posthoc analysis of the phase 3 ARCHES study showed that enzalutamide plus ADT led to an improvement in radiographic progression-free survival compared with ADT alone in men with mHSPC who had lymph node and/or bone metastatic spread.

According to Stenzl, the regimen was well tolerated and did not lead to a significant deterioration in patients’ quality of life.

Although all therapies have potential toxicities, brain-related adverse effects that have been associated with enzalutamide were not observed in the study, explains Stenzl. 

Previously, this combination was used in later-stage disease such as nonmetastatic or metastatic castration-resistant prostate cancer. However, these findings support the use of enzalutamide/ADT in mHSPC, concludes Stenzl.